Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2012

View Archived Issues

Monoclonal antibody improves behavioral performance in mouse model of Alzheimer's disease

Otsuka seeks approval for additional indication of Samsca

Merck & Co. reports on second quarter of 2012

Candidate IBS drug profiled preclinically

Novotyr Therapeutics designs novel IGF-I receptor inhibitors

Phase II study confirms efficacy of carfilzomib in multiple myeloma

Multiple dosing of BACE1 inhibitor for Alzheimer's-type dementia safe in phase I trial

Cleveland BioLabs secures funding for CBLB-612 development

Dabrafenib improves progression-free survival in phase III trial

Lupin presents new cannabinoid receptor ligands

Japanese researchers disclose new xanthine oxidase inhibitors

Alseres Pharmaceuticals issues worldwide Altropane sublicense

Novel paclitaxel prodrugs synthesized in U.S.

Kalydeco approved in Europe

Nymox reports on long-term follow-up studies of NX-1207

Idenix Pharmaceuticals restructures collaboration with Novartis Pharma

Stemgent acquires human tissue business

Prosetta Antiviral and Bristol-Myers Squibb form strategic alliance

Pfizer reports topline results from ORAL Start study

Depomed submits Serada NDA

ARRY-797 proof-of-concept trial meets primary endpoint

Lixte Biotechnology's lead anticancer agent clear to enter clinic

Shionogi files NDA for recombinant human leptin

Receipt confirmed of FDA complete response letter for HyQ BLA

Complete response filed for Ampligen NDA

FG-3019 obtains FDA orphan drug status

Stiefel acquires anti-inflammatory agent from Welichem Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...